AMAL ADELY: Open Payments
NPI 1447031695 · GREENWICH, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,492 in 68 payments from 15 companies in 2025. Trend: 2023 $66 · 2024 $1,369 · 2025 $1,492
Food & beverage: $1,492
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $427 |
| Alkermes, Inc. | 13 | $251 |
| Otsuka America Pharmaceutical, Inc. | 6 | $236 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $180 |
| Janssen Pharmaceuticals, Inc | 2 | $71 |
| Neurocrine BioSciences, Inc. | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 2 | $55 |
| Corium, LLC | 3 | $53 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $28 |
Products named: VRAYLAR, REXULTI, ARISTADA, CAPLYTA, SPRAVATO, INGREZZA, Azstarys, AUSTEDO XR.
Industry payments across CT — which companies pay providers there.
